Sona Nanotech Inc., who has recently acquired #TNVC2016 competitor Siva Therapeutics, has announced that Siva Therapeutics Inc. and its shareholders have waived the requirement for any further equity raise by Sona prior to the closed acquisition.
#TNVC2016 Competitor, Sona Nanotech has recently announced that they have recieved a second set of positive results of an independent assessment of its proprietary gold nanorod nanoparticles from the US National Nanotechnology Characterization Laboratory.
In a day and age where the efficient use of time has never been more paramount, #TNVC2016 competitor DocResponse has developed a system to effectively utilize doctors' time to help patients get the help they need faster! twitter.com/DocResponse/st…
#TNVC2016 competitor DocResponse has done some amazing things for the #medical community. We are so excited to see what strides this company makes next! twitter.com/DocResponse/st…
Sona Nanotech, who has recently acquired #TNVC2016 competitor Siva Therapeutics, LLC., has announced that Siva and its shareholders have waived the requirement for any further equity raise by Sona prior to the closed acquisition.
Sona Nanotech has entered into an agreement with #TNVC2016 Competitor @SivaTherapeutics to supply certain gold nanorod material for 'in-vivo' therapies for treating cancer.
Read more about Siva's Targeted Hyperthermia cancer Therapy (THT) here! proactiveinvestors.com/companies/news…